Perioperative Nivolumab Plus Ipilimumab for Localized Deficient Mismatch Repair/Microsatellite Instability–High Gastric/Gastroesophageal Junction Adenocarcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study
J. Clin. Oncol 2022 Aug 15;[EPub Ahead of Print], T André, D Tougeron, G Piessen, C de la Fouchardière, C Louvet, A Adenis, M Jary, C Tournigand, T Aparicio, J Desrame, A Lièvre, ML Garcia-Larnicol, T Pudlarz, R Cohen, S Memmi, D Vernerey, J Henriques, JH Lefevre, M SvrcekFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.